Aadi starts from scratch as it sells assets, licenses ADCs and raises new funds
In a major reset to round off the year, Aadi Bioscience is divesting its only marketed product and in-licensing a trio of ADCs developed by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
